PDCD1 and neoplasm: Treatment with the PARP14 inhibitor RBN012579, by enhancing the IFNγ signalling, re-sensitise these tumours to the PD-1 therapy, establishing PARP14 as an actionable target to reverse IFNγ-driven resistance mechanisms to immune checkpoint blockade therapy (Ref.